Abstract submission deadline: May 31, 2024 (23:00 pm CEST)

Abstracts may be submitted online via the congress website. Abstracts submitted by e-mail will not be accepted.

Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.

The title should be as brief as possible but long enough to clearly indicate the nature of the study. Abbreviations must not be used in the title. The title should not be written entirely in capital letters (e.g. NOT LIKE THIS).

Please indicate the topic from the abstract topics list and your preferred type of presentation (oral or poster). The Committee will endeavor to schedule abstracts according to authors’ preferences but reserves the right to decide on the final form of presentation.

Encore abstracts will be accepted unless they have been published in scientific journals.
Please structure the abstract as follows:

  • Introduction & Objectives: Describe the background and the purpose of the study
  • Materials & Methods: Describe the material and methods used to design the study
  • Results: Describe your results in a logical sequence
  • Conclusions: Emphasize new and important aspects of the study and conclusions that are drawn from them

The text shall not exceed 350 words including spaces (excluding title, authors bibliography and key words). The submission program will automatically calculate the number of characters in your abstract and will not allow submissions that exceed the maximum number of characters.

It is acceptable to include up to two tables, graphics, or images (jpg, jpeg, png, gif format, maximum size 2 MB in total) as part of the abstract.

All abstracts must be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. Abstracts will not be edited by the Congress Secretariat prior to publication, therefore please check the grammar and spelling carefully.

Please use generic names. The use of commercial drug names, brands and registered trademarks are strictly prohibited. Drugs should be referred to by the active substance or pharmacological designation.

No mention of pharmaceutical company names should be included in the abstract.